Allergy Therapeutics plc (AIM:AGY)

Market Cap	338.42M
Revenue (ttm)	55.66M
Net Income (ttm)	-35.65M
Shares Out	4.77B
EPS (ttm)	-0.01
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	395,373
Average Volume	552,714
Open	7.10
Previous Close	7.10
Day's Range	6.83 - 7.50
52-Week Range	0.07 - 8.00
Beta	1.00
RSI	59.48
Earnings Date	Jun 27, 2025

About Allergy Therapeutics

Allergy Therapeutics plc, a commercial biotechnology company, focuses on the diagnosis and treatment of allergic disorders. The company sells injectable and sublingual allergen-specific immunotherapies; and offers treatment of pollen-related allergies particularly to grasses, weeds, and trees, as well as diagnostics products. Its products include Pollinex Quattro, Oralvac, Venomil, Venom ATL Polistes Dominula, Synbiotics, and Acarovac Plus. It also develops Grass MATA MPL, a subcutaneous allergen-specific immunotherapy candidate that aims to ad...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1998
• Employees: 612
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: AGY

Financial Performance

In 2024, Allergy Therapeutics's revenue was 55.20 million, a decrease of -7.36% compared to the previous year's 59.59 million. Losses were -40.22 million, -6.63% less than in 2023.